Diabetes Mellitus Clinical Trial
Official title:
Improving Medication Adherence in the Alabama Black Belt
Verified date | October 2020 |
Source | Weill Medical College of Cornell University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Medication adherence is especially critical in regions like rural Alabama, where residents have among the worst health outcomes in the US. This project was designed in collaboration with our community member partners and builds on a 5-year partnership of community-engaged research on diabetes peer coaching interventions and our experience with peer storytelling. The investigators will test the hypothesis that an intervention designed within the Corbin and Strauss framework can improve adherence and health outcomes compared to usual care.
Status | Completed |
Enrollment | 473 |
Est. completion date | January 31, 2019 |
Est. primary completion date | January 31, 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 19 Years and older |
Eligibility | Inclusion Criteria: - adults - type 2 diabetes - taking medications for diabetes - medication non adherent Exclusion Criteria: - nursing home residence - plans to move away in the next year - advanced illnesses such as hemodialysis, cancer or dementia |
Country | Name | City | State |
---|---|---|---|
United States | Univeristy of Alabama at Birmingham | Birmingham | Alabama |
Lead Sponsor | Collaborator |
---|---|
Weill Medical College of Cornell University | Patient-Centered Outcomes Research Institute, University of Alabama at Birmingham |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Change in Medication Beliefs- Harm (Beliefs That Medications Are Harmful) | Beliefs about medications questionnaire scores range from 5-25; higher scores indicate stronger beliefs. | Baseline, 6 months | |
Other | Change in Medication Beliefs- Overuse (Concerns About the Way Doctors Use Medications) | Beliefs about medications questionnaire scores range from 5-25; higher scores indicate stronger beliefs. | Baseline, 6 months | |
Other | Change in Medication Beliefs-Necessity (Beliefs About the Necessity of Medications) | Beliefs about medications questionnaire scores range from 5-25; higher scores indicate stronger beliefs. | Baseline, 6 months | |
Other | Change in Medication Beliefs- Concerns (Concerns About the Negative Effects of Medications) | Beliefs about medications questionnaire scores range from 5-25; higher scores indicate stronger beliefs. | Baseline, 6 months | |
Primary | Change in Self Reported Medication Adherence | Patient-reported adherence to medications as a medication adherence score, from 0-3, where a higher score indicates worse adherence. | Baseline, 6 months | |
Primary | Change in Percentage of HbA1c | Hemoglobin A1c test to identify the average amount of glucose (sugar) present in a patient's blood. | Baseline, 6 months | |
Primary | Change in Blood Pressure | 2 BP measures were taken 1 minute apart using a LifeSource UA-789 digital blood pressure monitor. | Baseline, 6 months | |
Primary | Change in Low-Density Lipoprotein (LDL) Cholesterol | Finger stick, spectrophotometer to measure cholesterol level. | Baseline, 6 months | |
Secondary | Change in Quality of Life as Assessed With the Short Form 12- Mental Component | Short Form-12 Mental Component and Physical Component Summary scores range from 0-100; higher scores indicate greater quality of life. | Baseline, 6 months | |
Secondary | Change in Quality of Life as Assessed With the Short Form-12- Physical Component | Short Form-12 Mental Component and Physical Component Summary scores range from 0-100; higher scores indicate greater quality of life. | Baseline, 6 months | |
Secondary | Change in Medication Use Self-efficacy Score as Measured by SEAMS Scale and the Perceived Diabetes Self-Management Scale, Which is Associated With A1c | Medication use self-efficacy scores for range from 13-39; higher scores indicate higher levels of self-efficacy for medication adherence. | Baseline, 6 months | |
Secondary | Change in Diabetes-Specific Quality of Life | Diabetes specific quality of life will be assessed using the validated Diabetes Distress Scale.The DDS is a 17-item instrument that measures diabetes-related emotional distress. Participants rate the degree to which each item is problematic for them on a 6-point Likert scale, from 1 (no problem) to 6 (serious problem). A score of 3 or greater = moderate distress. | Baseline, 6 months | |
Secondary | Number of Physician Office Visits 6 Months | 6 months | ||
Secondary | Number of Hospital Stays at 6 Months | 6 months | ||
Secondary | Number of Emergency Visits at 6 Months | 6 months | ||
Secondary | Change in Diabetes Medication Counts | Change in number of diabetes medications. | Baseline, 6 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03743779 -
Mastering Diabetes Pilot Study
|
||
Completed |
NCT03786978 -
Pharmaceutical Care in the Reduction of Readmission Rates in Diabetes Melitus
|
N/A | |
Completed |
NCT01804803 -
DIgital Assisted MONitoring for DiabeteS - I
|
N/A | |
Completed |
NCT05039970 -
A Real-World Study of a Mobile Device-based Serious Health Game on Session Attendance in the National Diabetes Prevention Program
|
N/A | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Completed |
NCT04068272 -
Safety of Bosentan in Type II Diabetic Patients
|
Phase 1 | |
Completed |
NCT03243383 -
Readmission Prevention Pilot Trial in Diabetes Patients
|
N/A | |
Completed |
NCT03730480 -
User Performance of the CONTOUR NEXT and CONTOUR TV3 Blood Glucose Monitoring System (BGMS)
|
N/A | |
Recruiting |
NCT02690467 -
Efficacy, Safety and Acceptability of the New Pen Needle 34gx3,5mm.
|
N/A | |
Completed |
NCT02229383 -
Phase III Study to Evaluate Safety and Efficacy of Added Exenatide Versus Placebo to Titrated Basal Insulin Glargine in Inadequately Controlled Patients With Type II Diabetes Mellitus
|
Phase 3 | |
Completed |
NCT06181721 -
Evaluating Glucose Control Using a Next Generation Automated Insulin Delivery Algorithm in Patients With Type 1 and Type 2 Diabetes
|
N/A | |
Completed |
NCT05799976 -
Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure
|
N/A | |
Recruiting |
NCT04489043 -
Exercise, Prediabetes and Diabetes After Renal Transplantation.
|
N/A | |
Withdrawn |
NCT03319784 -
Analysis for NSAID VS Corticosteroid Shoulder Injection in Diabetic Patients
|
Phase 4 | |
Completed |
NCT03542084 -
Endocrinology Auto-Triggered e-Consults
|
N/A | |
Completed |
NCT02229396 -
Phase 3 28-Week Study With 24-Week and 52-week Extension Phases to Evaluate Efficacy and Safety of Exenatide Once Weekly and Dapagliflozin Versus Exenatide and Dapagliflozin Matching Placebo
|
Phase 3 | |
Recruiting |
NCT05544266 -
Rare and Atypical Diabetes Network
|
||
Completed |
NCT01892319 -
An International Non-interventional Cohort Study to Evaluate the Safety of Treatment With Insulin Detemir in Pregnant Women With Diabetes Mellitus. Diabetes Pregnancy Registry
|
||
Completed |
NCT05031000 -
Blood Glucose Monitoring Systems: Discounter Versus Brand
|
N/A | |
Recruiting |
NCT04039763 -
RT-CGM in Young Adults at Risk of DKA
|
N/A |